Medical management of diabetic retinopathy
A. K. Sjølie,
F. Møller,
Corresponding Author
A. K. Sjølie
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Correspondence to: A. K. Sjølie, Department of Ophthalmology, Odense University Hospital, DK-5000, Odense C, Denmark.Search for more papers by this authorF. Møller
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Search for more papers by this authorA. K. Sjølie,
F. Møller,
Corresponding Author
A. K. Sjølie
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Correspondence to: A. K. Sjølie, Department of Ophthalmology, Odense University Hospital, DK-5000, Odense C, Denmark.Search for more papers by this authorF. Møller
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Search for more papers by this authorAbstract
Although current treatment and prevention of diabetic retinopathy with laser photocoagulation, and tight metabolic and blood pressure control has reduced the risk of visual loss, there is still a need for additional therapies.
A literature review on medical therapies for diabetic retinopathy has been performed, and the following classes of drugs are discussed: blockers of the renin–angiotensin system, protein kinase C-β inhibitors, glitazones, somatostatin analogues, lipid-lowering drugs and anti-inflammatory drugs.
There is experimental and clinical data suggesting beneficial effect from several classes of drugs on diabetic retinopathy, and results from large clinical trials are awaited within the next 3–4 years.
References
- 1 Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14: S1–85.
- 2 Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994; 101: 1061–1070.
- 3 Moss SE, Klein R, Klein BEK. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998–1003.
- 4 Sjolie AK, Green A. Blindness in insulin-treated diabetic patients with age at onset less than 30 years. J Chronic Dis 1987; 40: 215–220.
- 5 Sjolie AK. Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol Suppl 1985; 172: 1–77.
- 6 Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997; 104: 252–260.
- 7 Herman WH, Teutsch SM, Sepe SJ, Sinnock P, Klein R. An approach to the prevention of blindness in diabetes. Diabetes Care 1983; 6: 608–613.
- 8 Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984; 119: 54–61.
- 9 Agardh E, Agardh CD, Hansson-Lundblad C. The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med 1993; 10: 555–559.
- 10 Cormack TG, Grant B, Macdonald MJ, Steel J, Campbell IW. Incidence of blindness due to diabetic eye disease in Fife 1990–91. Br J Ophthalmol 2001; 85: 354–356.
- 11
Icks A,
Trautner C,
Haastert B,
Berger M,
Giani G.
Blindness due to diabetes: population-based age- and sex-specific incidence rates.
Diabet Med
1997; 14: 571–575.
10.1002/(SICI)1096-9136(199707)14:7<571::AID-DIA384>3.0.CO;2-Y CAS PubMed Web of Science® Google Scholar
- 12 Trautner C, Icks A, Haastert B, Plum F, Berger M. Incidence of blindness in relation to diabetes. A population-based study. Diabetes Care 1997; 20: 1147–1153.
- 13 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
- 14 The Diabetes Control and Complications Trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995; 113: 36–51.
- 15 Wang PH. Tight glucose control and diabetic complications. Lancet 1993; 342: 129.
- 16 The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381–389.
- 17 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
- 18 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427–2432.
- 19 Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801–1815.
- 20 Klein R, Moss SE, Klein BE, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 1989; 149: 266–272.
- 21 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–713.
- 22 Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–1097.
- 23 Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85: 82–106.
- 24 Elliott A, Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 438–441.
- 25 Hamilton AM, Townsend C, Khoury D, Gould E, Blach RK. Xenon arc and argon laser photocoagulation in the treatment of diabetic disc neovascularization. Part 1. Effect on disc vessels, visual fields, and visual acuity. Trans Ophthalmol Soc UK 1981; 101: 87–92.
- 26 McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina 1985; 5: 5–10.
- 27 Pender PM, Benson WE, Compton H, Cox GB. The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology 1981; 88: 635–638.
- 28 Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766–785.
- 29 Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594–1602.
- 30 Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109: 1549–1551.
- 31 Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, Von Fricken MA et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503–510.
- 32 Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers 1999; 30: 706–714.
- 33 Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye 1999; 13: 145–150.
- 34 Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001; 14: 475–486.
- 35 Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ et al. Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995; 36: 1450–1458.
- 36 Danser AH, Van Den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68: 160–167.
- 37 Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619–628.
- 38 Wagner J, Jan Danser AH, Derkx FH, De Jong TV, Paul M, Mullins JJ et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin–angiotensin system. Br J Ophthalmol 1996; 80: 159–163.
- 39 Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141–145.
- 40 Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–450.
- 41 Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487.
- 42 Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473–1480.
- 43 Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309.
- 44 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845.
- 45 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
- 46 Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.
- 47 Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481–487.
- 48 The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–1792.
- 49 Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28–31.
- 50 Hogeboom v, BI, Polak BC, Reichert-Thoen JW, Vries-Knoppert WA, Van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002; 45: 203–209.
- 51 Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002; 86: 311–315.
- 52 Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S et al. Retinal neovascularization is prevented by blockade of the renin–angiotensin system. Hypertension 2000; 36: 1099–1104.
- 53 Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002; 13: 1773–1787.
- 54 Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 2001; 44: 883–888.
- 55 Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood–retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505–509.
- 56 Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284–289.
- 57 Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 1992; 152: 1225–1229.
- 58 Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 1995; 38: 437–444.
- 59 Chaturvedi N, Sjoelie AK, Svensson A. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002; 3: 255–261.
- 60 Study rationale and design of ADVANCE: action in diabetes and vascular disease—preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118–1120.
- 61 Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. Am J Med 1991; 90: 74S–76S.
- 62 Kinoshita N, Kakehashi A, Inoda S, Itou Y, Kuroki M, Yasu T et al. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 2002; 45: 735–739.
- 63 Alberti KG, Johnson AB, Taylor R. Gliclazide: metabolic and vascular effects—a perspective. Metabolism 1992; 41: 40–45.
- 64 Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171–179.
- 65 Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47: S263–S269.
- 66 Davis MD, Aiello LP, Milton RC, Sheetz MJ, Arora V, Vignati L. Diabetic retinopathy and macular edema progression rates in recent placebo-controlled clinical trials. Diabetes 2003; 52: A200.
- 67 Milton RC, Aiello LP, Davis MD, Arora V, Vignati L, Sheetz MJ. Initial results of the Protein Kinase C Beta Inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetes 2003; 52: A127.
- 68 Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568–1577.
- 69 Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes mellitus and related disorders. Clin Exp Hypertens 1999; 21: 121–136.
- 70 Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 2001; 119: 709–717.
- 71 Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15: 113–119.
- 72 Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98: 1261–1265.
- 73 Klein BE, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol 1999; 128: 652–654.
- 74 Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001; 24: 284–289.
- 75 Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 458–467.
- 76 Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969; 18: 285–291.
- 77 Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1–11.
- 78 Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112: 385–391.
- 79 Kopchick JJ, Okada S. Growth hormone receptor antagonists: discovery and potential uses. Growth Horm IGF Res 2001; 11 (Suppl. A): S103–S109.
- 80 Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 1986; 35: 416–420.
- 81 Danis RP, Bingaman DP. Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 1997; 104: 1661–1669.
- 82 Chantelau E. Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy. Ophthalmology 2002; 109: 2187–2188.
- 83 Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725–730.
- 84 Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33: 300–306.
- 85 Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 2002; 16: 493–509.
- 86 Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504–509.
- 87 Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57–61.
- 88 Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920–927.
Citing Literature
